About: http://webisa.webdatacommons.org/247039802

Property	Value
http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://www.w3.org/ns/prov#Entity
http://www.w3.org/ns/prov#value	Acumen holds IP and know-how for drug discovery approaches other than antibodies and in 2009 licensed its small molecule assembly blocker program to Merz Pharmaceuticals GmbH.
http://www.w3.org/ns/prov#wasQuotedFrom	b3cnewswire.com